Gene Therapy Clinical Trials
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
- Have been clinically diagnosed with primary IL or CM at the time of entry to a
previous Aura Biosciences sponsored clinical trial.
- Have received AU-011 bel-sar or assigned to a different cohort or treatment arm (sham,
SoC, etc.) an observation cohort in a previous Aura sponsored clinical trial.
Exclusion Criteria:
- None
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mariana Nunez
mnunez1@stanford.edu
I'm interested